Sameah Haider1, Martin J B Taphoorn2,3, Katharine J Drummond4,5, Tobias Walbert1. 1. Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, Michigan, USA. 2. Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands. 3. Department of Neurology, Haaglanden Medical Center, The Hague, The Netherlands. 4. Department of Neurosurgery, Royal Melbourne Hospital, Parkville, Victoria, Australia. 5. Department of Surgery, University of Melbourne, Parkville, Victoria, Australia.
Abstract
BACKGROUND: Meningiomas are the most common primary intracranial tumor in adults. Although frequently histologically benign, the clinical severity of a lesion may range from being asymptomatic to causing severe impairment of global function and well-being. The diversity of intracranial locations and clinical phenotypes poses a challenge when studying functional impairments, however, more recent attention to patient-reported outcomes and health-related quality of life (HRQOL) have helped to improve our understanding of how meningioma may impact a patient's life. METHODS: Treatment strategies such as observation, surgery, radiation, or a combination thereof have been examined to ascertain their contributions to symptoms, physical and cognitive functioning, disability, and general aspects of daily functioning. RESULTS: This review explores the multidimensional nature of HRQOL and how patients may be influenced by meningiomas and their treatment. CONCLUSION: Overall, treatment of symptomatic meningiomas is associated with improved HRQOL, cognitive functioning, and seizure control while tumor size, location, histologic grade, and epileptic burden are associated with worse HRQOL.
BACKGROUND:Meningiomas are the most common primary intracranial tumor in adults. Although frequently histologically benign, the clinical severity of a lesion may range from being asymptomatic to causing severe impairment of global function and well-being. The diversity of intracranial locations and clinical phenotypes poses a challenge when studying functional impairments, however, more recent attention to patient-reported outcomes and health-related quality of life (HRQOL) have helped to improve our understanding of how meningioma may impact a patient's life. METHODS: Treatment strategies such as observation, surgery, radiation, or a combination thereof have been examined to ascertain their contributions to symptoms, physical and cognitive functioning, disability, and general aspects of daily functioning. RESULTS: This review explores the multidimensional nature of HRQOL and how patients may be influenced by meningiomas and their treatment. CONCLUSION: Overall, treatment of symptomatic meningiomas is associated with improved HRQOL, cognitive functioning, and seizure control while tumor size, location, histologic grade, and epileptic burden are associated with worse HRQOL.
Authors: Eline Verhaak; Wietske C M Schimmel; Karin Gehring; Patrick E J Hanssens; Margriet M Sitskoorn Journal: Neurosurgery Date: 2021-04-15 Impact factor: 4.654
Authors: David van Nieuwenhuizen; Martin Klein; Lukas J A Stalpers; Sieger Leenstra; Jan J Heimans; Jaap C Reijneveld Journal: J Neurooncol Date: 2007-04-13 Impact factor: 4.130
Authors: T S Armstrong; T Mendoza; I Gning; I Gring; C Coco; M Z Cohen; L Eriksen; Ming-Ann Hsu; M R Gilbert; C Cleeland Journal: J Neurooncol Date: 2006-04-06 Impact factor: 4.130
Authors: Amir H Zamanipoor Najafabadi; Marthe C M Peeters; Linda Dirven; Daniel J Lobatto; Justus L Groen; Marieke L D Broekman; Saskia M Peerdeman; Wilo C Peul; Martin J B Taphoorn; Wouter R van Furth Journal: Neuro Oncol Date: 2017-07-01 Impact factor: 12.300
Authors: Amir H Zamanipoor Najafabadi; Marthe C M Peeters; Daniel J Lobatto; Marieke L D Broekman; Timothy R Smith; Nienke R Biermasz; Saskia M Peerdeman; Wilco C Peul; Martin J B Taphoorn; Wouter R van Furth; Linda Dirven Journal: Acta Neurochir (Wien) Date: 2017-09-27 Impact factor: 2.216
Authors: John Lynes; Gabriel Flores-Milan; Sebastian Rubino; John Arrington; Robert Macaulay; James K C Liu; Andre Beer-Furlan; Nam D Tran; Michael A Vogelbaum; Arnold B Etame Journal: Front Oncol Date: 2022-08-12 Impact factor: 5.738